Explore

TheStreetTheStreet
Bank of America has strong message for Merck stock investors

Bank of America has strong message for Merck stock investors

A private meeting with the drugmaker's top doctor points to the next make-or-break moment for shareholders.
Rapid ReadRapid Read
Singapore to Develop and Produce mRNA Influenza Vaccines to Bolster Pandemic Preparedness

Singapore to Develop and Produce mRNA Influenza Vaccines to Bolster Pandemic Preparedness

Singapore is actively pursuing the development and production of new mRNA influenza vaccines within its borders, a strategic move aimed at enhancing the nation's pandemic preparedness and building robust vaccine manufacturing capabilities. Health Minister Ong Ye Kung emphasized that this initiative is crucial for Singapore to effectively respond to future pandemics, including potential outbreaks from unknown pathogens like 'Disease X'. The Health Ministry plans to collaborate with organizations such as Hilleman Laboratories, which has its headquarters and manufacturing facility in Singapore, to advance these mRNA vaccine projects. mRNA technology, widely utilized during the COVID-19 pandemic, is favored for its flexibility in development and speed to market, making it an ideal platform for rapidly responding to fast-spreading diseases. The goal is to produce a commonly used vaccine, such as for influenza, during peacetime to maintain and 'keep warm' the manufacturing facilities and expertise. This effort i...
TrendlineTrendline
Merck's Experimental Eye Drug Matches Roche's VEGF Inhibitor, Raises Safety Concerns

Merck's Experimental Eye Drug Matches Roche's VEGF Inhibitor, Raises Safety Concerns

Merck's Experimental Eye Drug Matches Roche's VEGF Inhibitor, Raises Safety Concerns
TrendlineTrendline
Forge Nano and Nanexa Partner to Advance ALD-Coated Long-Acting Injectable Medicines Manufacturing

Forge Nano and Nanexa Partner to Advance ALD-Coated Long-Acting Injectable Medicines Manufacturing

Forge Nano and Nanexa Partner to Advance ALD-Coated Long-Acting Injectable Medicines Manufacturing
Rapid ReadRapid Read
Singapore to Boost Pandemic Preparedness by Developing and Producing mRNA Influenza Vaccines

Singapore to Boost Pandemic Preparedness by Developing and Producing mRNA Influenza Vaccines

Singapore is actively pursuing the development and production of new mRNA influenza vaccines within its borders. This initiative, spearheaded by Health Minister Ong Ye Kung, aims to significantly enhance the nation's pandemic preparedness and build robust vaccine manufacturing capabilities. The Ministry of Health (MOH) plans to collaborate with organizations like Hilleman Laboratories, which has its headquarters and manufacturing facility in Singapore, to achieve this goal. mRNA vaccine technology, widely utilized during the COVID-19 pandemic, is favored for its flexibility and speed in development and production, making it an ideal platform for responding to fast-spreading outbreaks. Minister Ong Ye Kung emphasized that while Singapore is currently "50 percent" prepared for future pandemics, substantial work remains, particularly in establishing domestic vaccine manufacturing and development capacity. The focus on influenza vaccines serves a dual purpose: addressing a common peacetime need while simultane...
Rapid ReadRapid Read
ZEISS and Harvard Advance 3D Spatial Biology for Cancer Research

ZEISS and Harvard Advance 3D Spatial Biology for Cancer Research

ZEISS is collaborating with Harvard's Laboratory of Systems Pharmacology (LSP) to advance 3D spatial biology, focusing on whole-cell segmentation and confocal optical sectioning for cancer research. This initiative aims to visualize cellular structures and vascular features across tissue depths, preserving their spatial relationship to surrounding tissue. The CyCIF process, developed at LSP, utilizes iterative cycles of staining, imaging, and bleaching with open-source reagents and protocols. Each round incorporates a nuclear marker for reliable 3D registration. This method generates massive datasets, ranging from 200 to 900 terabytes, across dozens of channels, enabling high-plex 3D imaging. The goal is to understand how immune and tumor cells are arranged within complex tissue microenvironments, particularly in melanoma, by mapping cellular communities and visualizing vascular structures in three dimensions.
AP NewsAP News
CDC vaccine recommendations are at a standstill, and unanswered questions are piling up

CDC vaccine recommendations are at a standstill, and unanswered questions are piling up

The Centers for Disease Control and Prevention’s vaccine recommendation process has been blown up in the past year, and decision-making has ground to a halt
Rapid ReadRapid Read
US FDA Launches INTERACT Program to Streamline Biologic Product Development

US FDA Launches INTERACT Program to Streamline Biologic Product Development

The U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) has introduced the INTERACT (INitial Targeted Engagement for Regulatory Advice on CBER ProducTs) program. This new initiative aims to facilitate early engagement between potential sponsors and FDA staff, providing advice on critical issues in the initial stages of biologic product development. The program's objective is to accelerate product development by addressing sponsors' questions, removing regulatory roadblocks, and establishing a clearer path for bringing products to patients. According to CBER director Peter Marks, INTERACT meetings will help streamline development by guiding sponsors on preclinical testing requirements, manufacturing aspects for first-in-human trials, initial clinical development strategies, and device or assay design considerations. The INTERACT program will replace the existing pre-pre-investigational new drug (IND) meeting program for all biologic products.
TrendlineTrendline
Merck's Remigromig Meets Primary Endpoint in Phase 2b/3 BRUNELLO Study for Diabetic Macular Edema

Merck's Remigromig Meets Primary Endpoint in Phase 2b/3 BRUNELLO Study for Diabetic Macular Edema

Merck's Remigromig Meets Primary Endpoint in Phase 2b/3 BRUNELLO Study for Diabetic Macular Edema
TrendlineTrendline
Scancell Holdings Secures Up to $25 Million in Debt Financing for iSCIB1+ Phase 3 Development

Scancell Holdings Secures Up to $25 Million in Debt Financing for iSCIB1+ Phase 3 Development

Scancell Holdings Secures Up to $25 Million in Debt Financing for iSCIB1+ Phase 3 Development
Rapid ReadRapid Read
Moderna's mRNA Vaccine Shows Promise in Reducing Melanoma Recurrence and Treating Other Cancers

Moderna's mRNA Vaccine Shows Promise in Reducing Melanoma Recurrence and Treating Other Cancers

Moderna's mRNA vaccine, developed in partnership with Merck, has demonstrated significant success in reducing the recurrence of melanoma in large-scale trials. This development is part of a broader effort by Moderna to expand its focus beyond COVID-19 vaccines into oncology and rare diseases. The vaccine works by rapidly activating patients' immune systems to target cancer cells. Beyond melanoma, the company is also reporting promising results in treating other challenging cancers, including glioblastoma, pancreatic, lung, and breast cancers. This expansion into various cancer types highlights the versatility and potential of mRNA technology in therapeutic applications. The ongoing research and clinical trials aim to validate these findings and bring new treatment options to patients with these difficult-to-treat conditions.
Detroit Free PressDetroit Free Press
Michigan, much of the U.S. in COVID-19 surge

Michigan, much of the U.S. in COVID-19 surge

Michigan and dozens of other states are in the midst of a COVID-19 surge, according to a new map from the Pandemic Mitigation Collaboration.